

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/667,295	09/17/2003	Peter N. Mascia	11696-047001	8833	
26191 FISH & RICH	26191 7590 03/21/2007 FISH & RICHARDSON P.C.			EXAMINER	
PO BOX 1022			FOX, DAVID T		
MINNEAPOL	IS, MN 55440-1022		ART UNIT	PAPER NUMBER	
		•	1638		
			MAIL DATE	DELIVERY MODE	
			03/21/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/667,295	MASCIA, PETER N.	
Examiner	Art Unit	
David T. Fox	1638	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 15 February 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. X The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires _____months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **NOTICE OF APPEAL** 2. The Notice of Appeal was filed on . A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. X The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: see attachment. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s); a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-28,30-36,50 and 52-63. Claim(s) withdrawn from consideration: 37-49. AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. A The request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attachment. 12.

☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). 20070220 13. ☐ Other: .

Application/Control Number: 10/667,295 Page 2

Art Unit: 1638

Attachment to Advisory Action. Item 3 (continued)

New issues: 112 second paragraph introduced by amendment of claim 53 and new claim 68, which are substantial duplicates of claims 54 and 36, respectively.

Failure to simplify: all rejections of record maintained.

Item 11 (continued)

Re 112 first paragraph rejections, the Table of known transcription activators does not appear to disclose gene sequences, only protein sequences. Furthermore, the existence of known transcription activators does not remedy unpredictability re their behavior in transgenic plants also containing male sterility genes and/or female sterility genes, as established by references previously cited by Examiner. References cited in IDS of 20 February 2007 were not supplied by Applicant, and so cannot be evaluated for their ability to rebut Examiner's position.

Re art rejections, the specification fails to clearly distinguish "genetic" male sterility from the transgenic male sterility taught by the prior art. No specific definition of "genetic" male sterility is given, and there is nothing in the specification to distinguish "genetic" from the now deleted "nuclear" male sterility. Thus, a reasonable interpretation of claim 50 and dependents results in the proper application of the 102 and 103 art cited by the Examiner. Furthermore, as no results were actually presented, the Examiner cannot evaluate the presence of unexpected results which might rebut the 103 rejections. It is also noted that Applicant's arguments re art rejections depend upon the entry of the after final amendment of 15 February 2007, which amendment was not in fact entered.

DAVID T. FOX
PRIMARY EXAMINER
GROUP-180-/(-3-8-)

Over